A psychedelic medical market valued at more than $373 billion
Since 2001, the date when medical cannabis was legalized in Canada, some investors have started to take an interest in this slowly opening market.
When the discussions began to be more serious on the recreational legalization of cannabis with the possible arrival of the government of Justin Trudeau, investors understood that a huge investment opportunity was opening up before them.
On October 20, 2015, the day after the Liberal Party of Canada was elected, Canopy Growth shares price jumped 21% to end the day at $2.72. It was followed by a vertiginous rise and very profitable for the investors who knew how to take advantage of this new emerging market with high potential.
The share price of Canopy Growth thereafter reached the peak of $76.68 on October 15, 2018 which represents a huge gain of 2700%.
But since the opening of the market, Canadian producers have known many problems since that time, some have gone bankrupt and others are struggling with huge debts while pofits are still scarce.
The arrival of the psychedelics market
While several smart investors have taken advantage of the rise of the cannabis market and withdrew in time, these same investors are now turning to a market that looks very much like that of cannabis in its early days. The psychedelic market.
There is a lot of promising research into a wide variety of problematic neurological and psychological conditions that have resisted more traditional treatments to date. It’s a potentially explosive industry in its infancy.
The psychedelic drug market can treat many conditions like:
-Major depressive disorder
-Post-traumatic stress disorder
-Addiction to opiates
As the psychedelic market opens up for the medical sector, interest is increasingly felt with the arrival of big players in the market with IPOs and acquisitions.
A medical market valued at more than $373 billion
Some experts have evaluated the medical market at more than $373 billion calculated from the main markets affordable by psychedelic therapy (neurogenic market): mental health drugs, therapy expenses, neurodegeneration drugs and cognitive improvement.
For its part, the recreational market is valued at $8-19.2 Billion calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Who are the publicly trades Psychedelics companies ?
More and more companies are entering the market. While some are still private and preparing to enter in the market (We will come back in another article), here are the main ones currently traded. :
MindMed | MMED (NEO). One of the best known at the moment is MindMed for which Bruce Linton is director. Mind Medicine is a psychedelics company with big plans to create a framework to treat mental illness using medicinal Psilocybin and MDMA.
This IPO was widely publicized and the share price even flirted with the $1.00 3 days after going public around $0.24. The share price is now at $0.60
Champignon Brands | SHRM (CSE). Champignon brand reflects the explosive potential of this market. The company entered the market on March 02, 2020 at $0.195. In less than 2 months, the share price is now $0.98 for an increase of 400%.
Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non- GMO and vegan certified.
Revive Therapeutics | RVV (CSE). Revive Therapeutics is not left behind in potential. They recently made a high of 360% since January 2020 while the company is far from reaching its full potential.
With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.
Psilocin has developed patent-pending formulation and production solutions for the active compound Psilocybin. The process encompassed with its intellectual property cover methods of production of Psilocybin-based formulations. The precisely dosed formulations will work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to U.S. Food and Drug Administration (“FDA”) approval in the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and a number of other diseases.
“We are combining our robust intellectual property portfolio in both psychedelic formulations and our drug delivery technology which is unique within the industry, and leveraging our research partnership with the University of Wisconsin-Madison to establish a specialty portfolio of psilocybin-based pharmaceuticals that we can advance to clinical trials and partnerships with other life sciences companies.”
-said Michael Frank, Revive’s Chief Executive Officer.
The potential of this company is immense due to the fact that they have a strong platform of intellectual property (IP) and patent portfolio other than the psychedelic market.
Last week the FDA recommended that the Company proceed directly into a Phase 3 confirmatory clinical trial (“Phase 3 study”) to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection in order to ensure expeditious evaluation of the safety and efficacy of Bucillamine.
Revive Therapeutics is really undervalued compared to its peers, RVV closed at $0.145 Friday. Visit RVV profile | HERE.
VISIT REVIVE THERAPEUTICS PROFILE | HERE
LAST ALERT MADE MORE THAN 360% !
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.
Disclosure : Revive Therapeutics Ltd is a paid clients of The Cannabis Stock.